CHEMICAL ENGINEERING JOURNAL
·
2025
·
IF 13.2
Yuetao Zhang,Zijie Li,Xuejiao Fan,Yan Liu,Zhiqi Li,Ziwei Zheng,Zixin Lin,Wenshan Zhang,Qingci Mu,Guangquan Mo,Yong Xia,Lei Mou
Noncommunicable diseases (NCDs) present formidable global health challenges, driving the need for innovative solutions in their management and prevention. This study introduces an integrated wearable device capable of stimulating, collecting, and analyzing sweat metabolites, furnishing personalized data crucial for NCDs management. The multimodal and multichannel flexible sensor array (MMFSA) enables real-time monitoring of biomarkers, including uric acid (UA), glucose, and lactate, alongside pH levels and skin surface temperature. The MMFSA was fabricated with a mass-production screen-printing device and functionalized with fast and in-situ electrodeposition of gold nanoparticles (AuNPs) and Ti 3 C 2 Tx multilayer Nanoflak (MXene) to enhance the electrochemical properties (Surface roughness: 96.8 nm and BET surface area: 8.3 m 2 /g). Leveraging microfluidic chip technology for efficient sweat collection and utilizing AuNPs and MXene-modified screen-printed electrodes (AuNPs&MXene-SPEs) for improved detection, the MMFSA exhibits favorable performance characteristics such as low sample consumption (20 μL), low limits of detection (0.854 μM for UA, 50.7 μM for glucose, and 3.15 mM for lactate), high sensitivity (0.750 nA/μM for UA, 0.359 nA/μM for glucose, and 0.103 nA/μM for lactate), specificity, and rapid response time. This wearable device transcends temporal and spatial constraints in patient management, offering a long-term, real-time, and non-invasive approach to sweat analysis, thereby holding promise for personalized healthcare monitoring and disease prevention strategies.
研究领域:
医学工程
·
生物传感器技术
·
健康管理
✓ 已验证
产品关联
DOI
高影响因子
RSC Advances
·
2020
·Vol. 10
·期 12
·7241-7250
·
IF 3.119
Tingting Tu,Bo Liang,Qingpeng Cao,Lu Fang,Qin Zhu,Yu Cai,Xuesong Ye
With the growing number of patients suffering from noninfectious chronic diseases, the consumption of point of care testing strips increases exponentially, particularly blood glucose testing strips, causing an increasingly severe conflict between strip recycling and the environment. In this paper, fully transient electrochemical strips are developed as a substitute for non-degradable strips. Proper explorations were made, including finding out suitable degradable substrates for strip-making among different degradable materials and optimization of degradable conducting paste. Taking advantage of dissolvable polymer-based materials and nontoxic carbon materials, the transient strips have validated electrochemical functionality to determine physiological levels of glucose with a sensitivity of 14.33 μA mM−1 cm−2 (correlation coefficient R2 is 0.99498) and reached full-degradation within a week after disposal. The interference experiment (negligible interference current response under 7%) and recovery tests (recovery ratio ranging from 92.46% to 102.47%) have illustrated its practical application in real sample detection. Such degradable-characterized testing strips can be widely used in chronic disease management with daily eco-friendly point of care testing, without potential pollution to the environment.
研究领域:
生物医学工程
·
环境科学
·
材料科学
·
分析化学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Nature Communications
·
2024
·Vol. 15
·期 1
·1-16
·
IF 14.7
Wu Xin,Yu Yuanhuan,Wang Meiyan,Dai Di,Yin Jianli,Liu Wenjing,Kong Deqiang,Tang Shasha,Meng Meiyao,Gao Tian,Zhang Yuanjin,Zhou Yang,Guan Ningzi,Zhao Shangang,Ye Haifeng
Gene therapies provide treatment options for many diseases, but the safe and long-term control of therapeutic transgene expression remains a primary issue for clinical applications. Here, we develop a muscone-induced transgene system packaged into adeno-associated virus (AAV) vectors (AAV MUSE ) based on a G protein-coupled murine olfactory receptor (MOR215-1) and a synthetic cAMP-responsive promoter (P CRE ). Upon exposure to the trigger, muscone binds to MOR215-1 and activates the cAMP signaling pathway to initiate transgene expression. AAV MUSE enables remote, muscone dose- and exposure-time-dependent control of luciferase expression in the livers or lungs of mice for at least 20 weeks. Moreover, we apply this AAV MUSE to treat two chronic inflammatory diseases: nonalcoholic fatty liver disease (NAFLD) and allergic asthma, showing that inhalation of muscone—after only one injection of AAV MUSE —can achieve long-term controllable expression of therapeutic proteins (ΔhFGF21 or ΔmIL-4). Our odorant-molecule-controlled system can advance gene-based precision therapies for human diseases.
研究领域:
基因治疗
·
药理学
·
分子生物学
·
慢性病管理
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Journal of Healthcare Engineering
·
2022
·Vol. 2022
·期 1
·2271937
·
IF 3.822
Xiangwen Yuan,Jiabin Zhang
Glaucoma is caused by excessive aqueous humor in the eye, resulting in a continuous or intermittent increase of intraocular pressure, which exceeds the tolerance of the eyeball and damages the optic nerve. Existing treatments for glaucoma do not work well or have significant side effects. Intraocular pressure signal is a very important physiological signal that needs real-time and accurate monitoring in glaucoma patients, especially in severe glaucoma patients. Therefore, long-term, real-time, and accurate monitoring of intraocular pressure is of great significance for the diagnosis and treatment of glaucoma patients. The use of wearable devices for real-time ocular diagnosis and treatment of glaucoma patients is an effective approach. However, the current commonly used intraocular pressure measurement and monitoring technology is difficult to meet the diagnosis and monitoring needs of glaucoma patients in terms of size, measurement accuracy, power consumption, and intelligence. Therefore, facing the needs of glaucoma disease treatment, this topic studies an implantable flexible intraocular pressure sensor for long-term continuous monitoring of intraocular pressure in glaucoma patients and mainly focuses on the working principle, structural design, process fabrication, measurement and control system, characterization, and performance test of the intraocular pressure sensor. It is of great significance for personalized and accurate treatment of glaucoma patients.
研究领域:
眼科
·
生物医学工程
·
传感器技术
·
转化医学
·
慢性病管理
✓ 已验证
DOI
高影响因子
BMC HEALTH SERVICES RESEARCH
·
2022
·Vol. 22
·期 1
·1-13
·
IF 2.908
Wu Jun,Qiao Jiajun,Nicholas Stephen,Liu Yunqiao,Maitland Elizabeth
Background China’s social medical insurance system faces challenges in financing, product coverage, patient health responsibility sharing and data security, which commercial health insurance companies can help address. Confronting accelerated population aging, the rapid increase of patients with chronic diseases and the maternal and child healthcare needs created by the three-child policy, the Chinese government has encouraged the development of commercial health insurance. But China's commercial health insurance companies face financial sustainability problems, limited product ranges and high operating costs. At the same time, the informatization level of China's healthcare industry, and the value of healthcare big data, is increasing. We analyze and describe the potential application of healthcare big data in the life cycle of China's commercial health insurance system and provide specific action plans for Chinese commercial health insurance companies; identify the challenges to commercial health insurers; and make recommendations for the application of big health data by commercial health insurers. Our recommendations inform healthcare policy makers on the development of commercial health insurance and the improvement of the healthcare financing system. We not only verify the value of healthcare big data, but also identify specific ways that healthcare big data plays in the development of commercial health insurance. Based on the research results, we recommend new policies for government and new uses of healthcare big data for commercial health insurance institutions. The benign development of commercial health insurance will improve the level of health services in China. Methods By interviewing health insurance managers (including actuaries, product managers, business executives, information technology medical workers, and commercial health insurance personnel) and by accessing research papers, industry reports, news reports and public information disclosure documents about commercial health insurance, we describe the impact of healthcare big data on the life cycle of commercial health insurance products and processes. Results We identify the issues and challenges of commercial health insurers in the use of healthcare big data, and advance specific strategies to expand the use of healthcare big data. In the life cycle of commercial health insurance products, healthcare big data can improve premium income, control medical costs and increase operational efficiency. First, healthcare big data can increase premiums, products and services by attenuating moral hazard and adverse selection problems, where high quality clients over-pay and high-risk clients underpay for health insurance. Second, healthcare big data can reduce medical expenses compensation pay-outs by promoting the establishment of a management medical system. Finally, the use of healthcare big data improves operational efficiency by increasing payment speeds, identifying fraud and increasing claim verification processes through automating payments and reducing offline processes. We discuss the obstacles to obtain healthcare big data confronting commercial health insurance companies. The sharing and data mining of healthcare big data brings privacy risks to the insured and there are significant differences in data standards and quality of healthcare big data that limit the application of healthcare big data in commercial health insurance. We recommend that national, regional and local government departments coordinate policies to facilitate the cooperation between commercial health insurance companies and regional healthcare big data platforms. In terms of technology, we recommend the establishment of data sharing platforms and data exchange mechanism across institutions and regions according to nation-wide standards and specifications. Government management departments should establish healthcare big data standards and specification system, promote the construction of healthcare big data and ensure the integrity, authenticity and reliability of health data. We recommend data quality continuous improvement and management mechanisms that combine technology and management. Government regulation should oversee commercial health insurance institutions and establish data security management systems to monitor and supervise the privacy of personal data. Conclusions Healthcare big data can play an important role in the development of China's commercial health insurance industry. Healthcare big data can increase commercial health insurers’ financial viability while providing improved, and cost-effective, products and services. By providing more and better information to insurers, healthcare big data attenuates the asymmetric information problem, addressing moral hazard and adverse selection problems. By combining hospital and medical organization management information systems with insurers’ data management, healthcare big data can help insurers set sustainable premiums, control medical costs and promote operational efficiency. At present, the informatization degree of China's healthcare industry remains limited. To improve the performances, products and services of commercial health insurers, we recommend government reforms in healthcare big data, such as expanding medical industry cooperation; further developing the processes of applying healthcare big data; augmenting data sharing; addressing privacy risks; setting data standards; and improving data quality.
研究领域:
卫生经济学
·
医疗保险
·
健康信息学
·
公共卫生政策
·
数据科学
·
风险管理
·
医疗信息化
·
慢性病管理
✓ 已验证
DOI
高影响因子
危险品化学品经营许可证（带存储）